Aclaris Therapeutics Inc Stock Price, News & Analysis

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company, has announced a significant leadership transition in its scientific team. Roland Kolbeck, Ph.D. has been appointed as the new Chief Scientific Officer, succeeding Joe Monahan, Ph.D., who will transition to a Special Scientific Advisor role through Q1 2026 as part of his planned retirement.

Dr. Kolbeck brings nearly 30 years of senior R&D leadership experience, most recently serving as CSO at Spirovant Sciences. His notable achievements include his role as VP and Head of Respiratory, Inflammation and Autoimmune Research at MedImmune, where six monoclonal antibodies from his portfolio received FDA approval. The transition comes as Aclaris continues to develop its portfolio of immuno-inflammatory product candidates, including next-generation kinase inhibitors and first-in-class bispecific antibodies.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has been added to both the Russell 2000® and Russell 3000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.

The inclusion comes as part of FTSE Russell's annual reconstitution process, which ranks the 4,000 largest US stocks by market capitalization. Notably, approximately $10.6 trillion in assets are benchmarked against Russell US indexes as of June 2024. Membership in these indexes will remain in place for one year.

Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory diseases, will deliver a corporate presentation at the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation is scheduled for Monday, June 30, 2025 at 11:30 AM EDT.

Investors and interested parties can access both the live and archived versions of the presentation through the Events page on the company's website, where it will remain available for a minimum of 30 days.

Aclaris Therapeutics (NASDAQ: ACRS) has initiated a Phase 1a/1b program for ATI-052, a novel bispecific antibody targeting both TSLP and IL-4R for immuno-inflammatory diseases. The program includes a Phase 1a single and multiple ascending dose study in healthy volunteers, followed by a Phase 1b proof of concept portion. ATI-052 is designed with high binding affinity to dual-block both upstream and downstream targets in Th2-mediated inflammation and allergic diseases. The Phase 1a portion will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052. Phase 1a results are expected by year-end 2025 with top-line results in early 2026, while Phase 1b results are anticipated in H2 2026.

Aclaris Therapeutics (NASDAQ: ACRS) has initiated a Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis. The trial follows successful Phase 2a results where bosakitug showed impressive efficacy with 94% of participants achieving EASI-75 scores and 88% achieving clear or nearly clear skin (IGA 0/1) at week 26. The new randomized, double-blind, placebo-controlled global study will evaluate approximately 90 patients, with primary endpoint measuring EASI score changes at week 24. Bosakitug, positioned as a potential best-in-class anti-TSLP therapeutic monoclonal antibody, demonstrates superior potency, residence time, and unique TSLP binding characteristics. Top-line results are expected in the second half of 2026.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, has announced its participation in two major healthcare conferences in June 2025. The company's CEO Dr. Neal Walker and senior leadership team will participate in:

1. A fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2025, at 10:30 AM EDT

2. A fireside chat at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami on June 11, 2025, at 1:20 PM EDT

Live webcasts of both events will be available on the Events page of Aclaris' website and will remain accessible for at least 30 days.

Aclaris Therapeutics (NASDAQ: ACRS), a clinical-stage biopharmaceutical company specializing in immuno-inflammatory disease treatments, has announced its participation in the HC Wainwright "HCW@Home" virtual series. The company's CEO Neal Walker and senior leadership team will engage in a fireside chat scheduled for May 16, 2025, at 1:00 PM EDT. Investors and interested parties can access the live webcast and a 30-day replay through the Events page on the company's website at aclaristx.com.

Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 2025 financial results and provided updates on its immuno-inflammatory drug pipeline. The company ended Q1 with $190.5 million in cash, extending runway through H1 2028. Net loss was $15.1 million, improved from $16.9 million in Q1 2024. Key pipeline updates include: - Plans to initiate Phase 2 trial of bosakitug (ATI-045) in atopic dermatitis in Q2 2025 - Seeking development partners for bosakitug in respiratory indications - Expecting Phase 2a trial results for ATI-2138 in June 2025 - Received FDA clearance for ATI-052 IND application - Appointed Dr. Jesse W. Hall as Chief Medical Officer R&D expenses increased to $11.6 million (vs $9.8M in Q1 2024), while G&A expenses decreased to $6.1 million (vs $6.8M). The company maintains focus on clinical execution and efficient capital utilization.

Aclaris Therapeutics has appointed Jesse Hall, M.D. as Chief Medical Officer, strengthening its leadership in immuno-inflammatory disease therapeutics. Dr. Hall brings extensive experience in clinical development, particularly in immunology and antibody development.

Dr. Hall's previous role was CMO at AltruBio, and he has held positions at notable companies including Sublimity Therapeutics, Ardea Biosciences (AstraZeneca), Amgen, and Abbott Labs. His track record includes work on successful monoclonal antibodies like HUMIRA and PROLIA.

As part of his employment package starting May 1, 2025, Dr. Hall will receive:

• 510,000 nonstatutory stock options
• 145,500 restricted stock units

These equity awards will vest over four years, with 25% vesting annually, subject to continued employment. The grants are part of Aclaris' 2024 Inducement Plan, designed for new employees under Nasdaq Rule 5635(c)(4).